Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 2
2009 1
2010 3
2011 2
2012 2
2013 3
2014 2
2016 1
2017 1
2018 5
2019 2
2020 2
2021 4
2022 4
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Mackensen A, et al. Among authors: aigner m. Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15. Nat Med. 2022. PMID: 36109639
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G. Mougiakakos D, et al. Among authors: aigner m. N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725. N Engl J Med. 2021. PMID: 34347960 No abstract available.
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: aigner m. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
CD19-targeted CAR T cells in refractory antisynthetase syndrome.
Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, Rösler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schröder R, Uder M, Roemer F, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: aigner m. Lancet. 2023 Mar 11;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5. Epub 2023 Feb 15. Lancet. 2023. PMID: 36930673 No abstract available.
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells.
Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M, Kretschmann S, Reimann H, Harrer T, Bayerl N, Boeltz S, Wirsching A, Taubmann J, Rösler W, Spriewald B, Wacker J, Atzinger A, Uder M, Kuwert T, Mackensen A, Schett G. Bergmann C, et al. Among authors: aigner m. Ann Rheum Dis. 2023 Aug;82(8):1117-1120. doi: 10.1136/ard-2023-223952. Epub 2023 May 5. Ann Rheum Dis. 2023. PMID: 37147112 Free PMC article. No abstract available.
Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Mackensen A, et al. Among authors: aigner m. Nat Med. 2023 Nov;29(11):2956. doi: 10.1038/s41591-022-02091-9. Nat Med. 2023. PMID: 36329355 No abstract available.
Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy.
Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, Müller F, Aigner M, Völkl S, Mackensen A, Schett G, Basu S. Nunez D, et al. Among authors: aigner m. Mol Ther Methods Clin Dev. 2023 Sep 1;31:101104. doi: 10.1016/j.omtm.2023.08.023. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 37744005 Free PMC article.
Role of CAR T Cell Metabolism for Therapeutic Efficacy.
Rial Saborido J, Völkl S, Aigner M, Mackensen A, Mougiakakos D. Rial Saborido J, et al. Among authors: aigner m. Cancers (Basel). 2022 Nov 4;14(21):5442. doi: 10.3390/cancers14215442. Cancers (Basel). 2022. PMID: 36358860 Free PMC article. Review.
Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.
Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, Gary R, Kretschmann S, Boeltz S, Atzinger A, Kuwert T, Roemer F, Uder M, Mackensen A, Schett G. Taubmann J, et al. Among authors: aigner m. Rheumatology (Oxford). 2024 Jan 4;63(1):e12-e14. doi: 10.1093/rheumatology/kead330. Rheumatology (Oxford). 2024. PMID: 37432378 Free PMC article. No abstract available.
47 results